Search

MVA3000

MVA3000 is an attenuated smallpox vaccine that is being developed for use in people for whom the traditional smallpox vaccine is contraindicated, such as patients with disorders of the immune system or

Romidepsin

Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy

Arzoxifene

Deucravacitinib

[L43150] It was later approved by Health Canada in November 2022 [L44216] and by the European Medicines Agency in March 2023.[L45788] … [A246943] Deucravacitinib was first approved by the FDA in September 2022 to treat moderate-to-severe plaque psoriasis.

Risdiplam

[L12615] It increases systemic SMN protein concentrations by improving the efficiency of _SMN2_ gene transcription. … [L15351,A216871] Risdiplam was approved by the FDA in August 2020 for the treatment of spinal muscular atrophy (SMA).

Sulfamethazine

A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.

XL844

XL844 is investigated for the use and treatment solid tumors. XL844 is a solid.

Mecamylamine

Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.

Ceftibuten

Ceftibuten is a third-generation cephalosporin antibiotic that is orally-administered. It is typically used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.

Topotecan

It works by inhibiting DNA topoisomerases, type I.